| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8770990 | The Journal of Urology | 2018 | 14 Pages |
Abstract
Immunotherapies for urothelial carcinoma have shown clinical efficacy in select patients as well as a manageable safety profile. Studies are ongoing with the aim of expanding the proof of efficacy in metastatic disease and providing additional treatment options for patients with earlier stages of urothelial carcinoma.
Keywords
TCGAnonMIBCCTLA-4FDAMIBCNMIBCTURBTFGFR3ICBMUCPD-1ORRPD-L1BCGAPCBacillus Calmette-Guérinantigen-presenting cellUnited States Food and Drug AdministrationThe cancer genome atlasimmunotherapyinterferonIFNoverall survivalcluster of differentiationDORtransurethral bladder tumor resectionMuscle invasive bladder cancerUrinary bladder neoplasmsurothelial carcinomaprogrammed cell death ligand-1duration of responseProgrammed cell death 1 receptorProgrammed cell death-1overall response ratecomplete responsemetastatic urothelial carcinomaCarcinomaFibroblast Growth Factor Receptor 3
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Arlene O. Siefker-Radtke, Andrea B. Apolo, Trinity J. Bivalacqua, Philippe E. Spiess, Peter C. Black,